About ConcePTION

ConcePTION is a project funded by the Innovative Medicines Initiative, a private public partnership. The project was launched in April 2019.

We believe that we have an important societal obligation to radically and rapidly reduce uncertainty about the effects of medication used during pregnancy and breastfeeding to benefit women in making informed decisions about medications used before, during and after pregnancy.

Reporting medicine use in pregnancy

Did you use any medicines when you were pregnant? Here is how you and your health care provider can report what we call an exposure.

Ten principles for stakeholder engagement in the ConcePTION project

The ConcePTION project is building much-needed knowledge for women and health care professionals. To achieve our goal of building an ecosystem for medicine safety in pregnancy and breastfeeding, we need to engage with women, their partners, their doctors, pharmacists, midwives and nurses, the companies that develop medicines and the authorities that approve them and decide what becomes available to patients. Our goal is to work in an open and inclusive way, with the spirit of mutual respect and trust. Here is how we engage with stakeholders in an ethical way.

News

Dec
16
2021
200 million women get pregnant each year, most of them use at least one medication during pregnancy, but safety data are lacking! The ConcePTION project is developing an ecosystem to generate robust evidence on medicines safety information in pregnancy and breastfeeding. Because of the diversity of data across many sites and countries, the ConcePTION common data model is an important part of this safety evidence ecosystem. It enables consistent research approaches to be applied to a large number of datasets across Europe. Something that is needed to fill the knowledge gap regarding medicine safety in pregnancy and breastfeeding. The common data model, and how to harmonize data to support knowledge generation on the safety of medicines for pregnant and breastfeeding women, is described in a paper recently published in Clinical Pharmacology & Therapeutics.  | READ MORE >>
Dec
09
2021
On 25 January 2022, the IMI ConcePTION project is organising an online workshop on improving how we collect information to understand the risks and benefits of medicine use in pregnancy and breastfeeding. We invite women, their partners, health care professionals, researchers and representatives from companies that develop medicines and authorities that approve them to join us. Your input will help us fill some of the knowledge gaps on the safety of medicines in pregnancy and breastfeeding, and help us to understand where there are barriers and problems with the existing systems! | READ MORE >>
Nov
08
2021
This week is Safe Motherhood Week, the annual awareness week on maternal and neonatal health. This year’s theme is the impact of COVID-19 on maternal health and reproductive care, and the need to reduce the information gap on the safety of medication during pregnancy and breastfeeding. Highlighting the importance of maternal health, especially in light of the current pandemic, and aiming to raise awareness of the persistent information gap.  | READ MORE >>

Twitter

Inconsistent information on medicine safety in #pregnancy and #lactation can have consequences for women and babies. We have analysed inconsistencies in online information sources for #patients and health care professionals in four European languages! 👇https://www.tandfonline.com/doi/full/10.1080/14740338.2021.1935865

The ConcePTION consortium

The project unites an unprecedented 88 organizations from 22 countries, including the European Medicines Agency, drug manufacturers, academia, public health organizations, and teratology networks to innovate new solutions to a decades-long public health issue.

OUR CONSORTIUM
»

The ConcePTION project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821520. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.